

## Preferred provider use

Phase I CRO outsourcing



Phase II/III
CRO outsourcing



Phase IV CRO outsourcing



eTMF software outsourcing



Small molecule (SM) API CMO outsourcing



SM drug product CMO outsourcing



Biologic API CMO outsourcing




Biologic drug product CMO outsourcing



About half of sponsors use preferred providers for outsourced clinical, manufacturing, or software work. However, there are differences in usage rates between large and non-large sponsors; large sponsors are more likely to use preferred providers.

## Number of preferred providers



Phase I CRO
Phase II/III CRO
Phase IV CRO

eTMF software
SM API CMO
SM drug product CMO
Biologic API CMO
Biologic drug product CMO

0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 55% % of Respondents

Respondents indicated their companies tend to have more preferred providers for manufacturing work, and fewer for outsourced technologies. About half of sponsors that have preferred providers for technology only have one provider on their list.

## Preferred provider selection drivers

Expectations for data quality



Global footprint\*





Low

data quality

**Expectations for** 

Top 5 driver for **30%** 

of CRO respondents

footprint\*

Global

Top 5 driver for **34%** 

of CRO respondents

cost

Low

Top 5 driver for

of CRO respondents

Metrics for meeting overall project timelines



Top 5 driver for **1796** of CRO respondents

Operational excellence



47% of CRO respondents

Prior positive experience with service provider



Top 5 driver for **36%** of CRO respondents

Project manager quality



Top 5 driver for **28%** of CRO respondents

Provider responsiveness



Top 5 driver for **22%** of CRO respondents

Therapeutic expertise



Top 5 driver for **37%** of CRO respondents

\*Phase I respondents indicating the importance of Location of Phase I units in different global locations were coded into the *Global footprint* table.

The most important attribute for sponsors to include a CRO on their preferred provider list across all research phases is *Operational excellence*. However, each attribute was indicated as a Top 5 driver for at least 20% of respondents in one or more phases.